| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

27 September - 1 October 2021

BIO-Spain 2021

23-24 September 2021

International Conference on Autism ICA-2021

22 September 2021

ORYZON to present new clinical data and corporate updates at international conferences in September and October

21 September 2021

Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat

29 July 2021

ORYZON reports results and corporate update for first half ended June 30, 2021

13 July 2021

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

9 July 2021

ORYZON presents safety and efficacy data of vafidemstat from the Phase II ESCAPE trial in severe CoVID-19 patients at ECCMID-2021

14-15 July 2021

Epigenetic Therapeutic Target Summit

9-12 July 2021

31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2021)

24-25 June 2021

Spring European Virtual MidCap Event

Pagination

First page «
Previous page ‹
Page 26
Page 27
Page 28
Page 29
Current page 30
Page 31
Page 32
Page 33
Page 34
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel